硬皮病,又称系统性硬化症(Systemic Sclerosis, SSc),是一种复杂的自身免疫性结缔组织疾病,其特征是皮肤和内脏器官的广泛纤维化、弥漫性微血管病变和免疫调节障碍。肠道菌群通过调节炎症和成纤维细胞分化过程从而促进了硬皮病患者的皮...硬皮病,又称系统性硬化症(Systemic Sclerosis, SSc),是一种复杂的自身免疫性结缔组织疾病,其特征是皮肤和内脏器官的广泛纤维化、弥漫性微血管病变和免疫调节障碍。肠道菌群通过调节炎症和成纤维细胞分化过程从而促进了硬皮病患者的皮肤、肺、心脏和胃肠道组织的纤维化并且对免疫系统产生影响。该文综述了硬皮病患者的肠道菌群特征以及相关药物、营养支持、饮食干预、益生菌和粪便菌群移植在硬皮病治疗方面的最新研究进展,为临床防治硬皮病提供新的理念和方法。Scleroderma, also known as Systemic Sclerosis (SSc), is a complex autoimmune connective tissue disease characterized by extensive fibrosis of the skin and internal organs, diffuse microangiopathy, and impaired immune regulation. The intestinal flora promotes fibrosis in skin, lung, heart and gastrointestinal tissues of scleroderma patients by regulating inflammatory and fibroblast differentiation processes and has an impact on the immune system. This article reviews the characteristics of the gut flora in scleroderma patients and recent research advances in the treatment of scleroderma with relevant medications, nutritional support, dietary interventions, probiotics, and fecal microbiota transplantation to provide new concepts and approaches for the clinical management of scleroderma.展开更多
文摘硬皮病,又称系统性硬化症(Systemic Sclerosis, SSc),是一种复杂的自身免疫性结缔组织疾病,其特征是皮肤和内脏器官的广泛纤维化、弥漫性微血管病变和免疫调节障碍。肠道菌群通过调节炎症和成纤维细胞分化过程从而促进了硬皮病患者的皮肤、肺、心脏和胃肠道组织的纤维化并且对免疫系统产生影响。该文综述了硬皮病患者的肠道菌群特征以及相关药物、营养支持、饮食干预、益生菌和粪便菌群移植在硬皮病治疗方面的最新研究进展,为临床防治硬皮病提供新的理念和方法。Scleroderma, also known as Systemic Sclerosis (SSc), is a complex autoimmune connective tissue disease characterized by extensive fibrosis of the skin and internal organs, diffuse microangiopathy, and impaired immune regulation. The intestinal flora promotes fibrosis in skin, lung, heart and gastrointestinal tissues of scleroderma patients by regulating inflammatory and fibroblast differentiation processes and has an impact on the immune system. This article reviews the characteristics of the gut flora in scleroderma patients and recent research advances in the treatment of scleroderma with relevant medications, nutritional support, dietary interventions, probiotics, and fecal microbiota transplantation to provide new concepts and approaches for the clinical management of scleroderma.
